Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Leber’s hereditary optic neuropathy (LHON) is a mitochondrially inherited disease leading to blindness. A mitochondrial DNA point mutation at the 11778 nucleotide site of the NADH dehydrogenase subunit 4 ( ND4 ) gene is the most common cause. The aim of this study was to evaluate the efficacy and safety of a recombinant adeno-associated virus 2 (AAV2) carrying ND4 (rAAV2-ND4) in LHON patients carrying the G11778A mutation. Nine patients were administered rAAV2-ND4 by intravitreal injection to one eye and then followed for 9 months. Ophthalmologic examinations of visual acuity, visual field and optical coherence tomography were performed. Physical examinations included routine blood and urine. The visual acuity of the injected eyes of six patients improved by at least 0.3 log MAR after 9 months of follow-up. In these six patients, the visual field was enlarged but the retinal nerve fibre layer remained relatively stable. No other outcome measure was significantly changed. None of the nine patients had local or systemic adverse events related to the vector during the 9-month follow-up period. These findings support the feasible use of gene therapy for LHON.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Different trials have demonstrated the safety and efficacy of gene therapy using an AAV vector, delivered through an intravitreal route, for LHON.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two similar gene therapy programmes led by groups in the USA25,26 and China,27–30 have targeted the m.11778G>A mutation in MT-ND4, also using a viral vector containing a cDNA coding the human wild-type mitochondrial ND4 protein.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Mitochondrial dysfunction as a cause of optic neuropathies
Carelli, V., Ross-Cisneros, F. N., & Sadun, A. A. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2003.10.003 · Cited by 839
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Mackey, D. A., Oostra, R., Rosenberg, T., Nikoskelainen, E. K., Brontë-Stewart, J., Poulton, J., Harding, A. E., Govan, G. G., Bolhuis, P. A., & Nørby, S. (1996) · PubMed Central · Cited by 339
Ueber hereditäre und congenital-angelegte Sehnervenleiden
Leber, T. (1871) · Albrecht von Græfe's Archiv für Ophthalmologie · doi:10.1007/bf01694557 · Cited by 272
Oestrogens ameliorate mitochondrial dysfunction in Leber’s hereditary optic neuropathy
Giordano, C., Montopoli, M., Perli, E., Orlandi, M., Fantin, M., Ross-Cisneros, F. N., Caparrotta, L., Martinuzzi, A., Ragazzi, E., Ghelli, A., et al. (2011) · Brain · doi:10.1093/brain/awq276 · Cited by 252
Idebenone Treatment In Leber's Hereditary Optic Neuropathy
Carelli, V., La Morgia, C., Valentino, M. L., Rizzo, G., Carbonelli, M., De Negri, A. M., Sadun, F., Carta, A., Guerriero, S., Simonelli, F., et al. (2011) · Brain · doi:10.1093/brain/awr180 · Cited by 241
Research works printed but not linked: 2
- Pei, H., Wan, X., Hu, W., Dong, X. & Li, B. Constructing and detecting a new rAAV2/2-ND4. Eye Science 28, 55–59 (2013).
- Gao, J. et al. Comparison of immunosuppressive effects and ND4 expression among different immunosuppressive strategies following AAV2-ND4 gene treatment for Leber hereditary optic neuropathy. J. Huazhong Acta Med. Univ. Sci. Tech. 42, 187–191 (2013).
Cited by
Items 101–181 of 181
Subramaniam, M. D., Chirayath, R. B., Iyer, M., Nair, A. P., & Vellingiri, B. (2022) · International Ophthalmology · doi:10.1007/s10792-022-02267-9 · Cited by 11
Yuan, J., Zhao, J., Ye, C., Pang, L., Zhang, X., Luk, A. Y., Du, Y., Fan, K. Y., Zhang, X., Li, B., et al. (2023) · BioMed Research International · doi:10.1155/2023/1107866 · Cited by 10
“For further meta-analysis, 4 articles [45–48] investigating the same patient cohort as other included articles [49, 50], 1 article [51] with only 1 G11778A mutation carrier converting from carrier to affected patient, and 2 articles [52, 53] reporting extreme value of proportion of G11778A among the three primary muta…”
Self-citationGene therapy for Leber hereditary optic neuropathy
Battista, M., Carelli, V., Bottazzi, L., Bandello, F. M., Cascavilla, M. L., & Barboni, P. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2359015 · Cited by 10
“Another Chinese-based trial assessed the safety and efficacy of an intravitreal injection of a different AAV2 construct (rAAV2-ND4) in nine patients affected by the m.11778 G>A/ MT-ND4 mutation (www.clinicaltrials.gov NCT01267422) [51].”
BackgroundParadigm Shifts in Ophthalmic Diagnostics.
Sebag, J., Sadun, A. A., & Pierce, E. A. (2016) · Europe PMC (PubMed Central) · Cited by 11
Starr, C. R., & Chen, B. (2023) · Vision Research · doi:10.1016/j.visres.2023.108196 · Cited by 10
Vector Shedding and Immunogenicity Sampling for Retinal Gene Therapy
Barnard, A. R., Rudenko, A., & MacLaren, R. E. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_27 · Cited by 9
Czajka, M., Zajkowska, A., Gawlak, M., Bujalska‐Zadrożny, M., & Małecki, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14448 · Cited by 9
Yang, Y., Chang, Y., Lai, Y.-H., Tsai, P., Hsiao, Y., Nguyen, L. H., Lim, X.-Z., Weng, C.-C., Ko, Y., Yang, C., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10040788 · Cited by 9
“Gene therapy that delivers the ND4 gene to the patients holds promises in LHON patients, but its sustained efficacy and safety remain unclear in clinical trials [33].”
BackgroundLeber hereditary optic neuropathy gene therapy
Lam, B. L. (2023) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001028 · Cited by 12
Hinsch, V. G., Boye, S. L., & Boye, S. E. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.252 · Cited by 12
Zhang, Y., Yuan, J., Liu, H., Tian, Z., Liu, S.-W., & Li, B. (2019) · Current Gene Therapy · doi:10.2174/1566523219666190618094505 · Cited by 8
Self-citationSharif, N. A. (2022) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2201116 · Cited by 10
Leber’s hereditary optic neuropathy – current status of idebenone and gene replacement therapies
Klopstock, T., Zeng, L. H., & Priglinger, C. (2025) · Medizinische Genetik · doi:10.1515/medgen-2024-2066 · Cited by 10
Update on Gene Therapy Clinical Trials for Eye Diseases
Lonfat, N., Leon, L. M., Punzo, C., & Khanna, H. (2025) · Human Gene Therapy · doi:10.1177/10430342251379824 · Cited by 8
Leber Hereditary Optic Neuropathy: Molecular Pathophysiology and Updates on Gene Therapy
Chi, S.-C., Cheng, H., & Wang, A.-G. (2022) · Biomedicines · doi:10.3390/biomedicines10081930 · Cited by 8
“[52] (Wuhan group) recruited nine patients into their phase 1 study (NCT01267422) in 2011.”
BackgroundAttenuation of Inherited and Acquired Retinal Degeneration Progression with Gene-based Techniques
Cho, G. Y., Bolo, K. A., Park, K. S., Sengillo, J. D., & Tsang, S. H. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0377-1 · Cited by 8
Progress in diagnosis and treatment of Leber’s hereditary optic neuropathy
Ma, Q., Sun, Y., Lei, K., & Luo, W. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02389-2 · Cited by 6
Diagnostik und Therapie Mitochondrialer Erkrankungen
Radelfahr, F., & Klopstock, T. (2018) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-0621-9255 · Cited by 8
Movement Disorders and Inherited Metabolic Disorders: Recognition, Understanding, Improving Outcomes
(2020) · Cambridge University Press eBooks · doi:10.1017/9781108556767 · Cited by 10
The rAAV2-ND1 gene therapy for Leber hereditary optic neuropathy
Li, X., Yuan, J. J., Jia, Q., Ruan, K., Li, B., Dan, Y., & Zhang, Y. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06776-y · Cited by 5
“The doses were chosen with reference to prior clinical trials of ND4 mutation-associated LHON [7] and our animal studies on ND1 mutation-associated LHON.”
Self-citationExperimental therapy for mitochondrial diseases
Viscomi, C. F., & Zeviani, M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00013-0 · Cited by 5
Orphan drug development in China ‒ Turning challenges into opportunities
Jin, X., & Chen, L. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01025 · Cited by 5
“In addition, a team of scientists from Tongji Medical College have, in collaboration with FivePlus Molecular Medicine Institute in Beijing, successfully conducted a long-term trial of gene therapy in human patients with a rare genetic disorder known as Leber's hereditary optic neuropathy (LHON) (17,18), more than 10 y…”
BackgroundRecent advances in neuro-ophthalmology
Bassi, S. T., Newman, N. J., Chen, J. J.-W., Tisavipat, N., Mollan, S. P., Moss, H. E., & Miléa, D. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_594_24 · Cited by 8
“Wan (2016) [25] Yang (2016) [26] Safety Yuan (2020) [27] Safety and Interventional, open‑label 8 (≥9 years) Single IVT rAAV2‑ND4 in one eye of the eight unilaterally treated patients in Wan (2016) [25] and Yang (2016) [26] >12”
Yang, S., Chen, C., Yuan, J., Wang, S., Wan, X., He, H., Ma, S., & Li, B. (2019) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000797 · Cited by 5
Self-citationApplications of Virus Vector–Mediated Gene Therapy in China
Lin, Q., Deng-gao, W., Zhang, Z., & Liu, D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.238 · Cited by 5
Lyu, L., Beibei, Q. I. E., He, Y., Chen, F., & Liu, B. C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07420-3 · Cited by 5
“Only mild and well controlled intraocular inflammation was recorded and unrelated to the medicine, since no difference of the inflammation was observed between bilaterally and unilaterally treated patients [76, 79, 88, 89].”
Targeted Mitochondrial Genome Elimination
Bacman, S. R., Pereira, C. V., & Moraes, C. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_24 · Cited by 4
Leber hereditary optic neuropathy
Mazunin, I., & Volodko, N. V. (2018) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2018134292-96 · Cited by 6
Genes and Gene Therapy in Inherited Retinal Disease
Shughoury, A., Ciulla, T. A., Bakall, B., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000377 · Cited by 4
Allotopic Expression of ATP6 in Mouse as a Transgenic Model of Mitochondrial Disease
Dunn, D. A., & Pinkert, C. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1270-5_1 · Cited by 4
Allotopic expression of ATP6 in the mouse as a transgenic model of mitochondrial disease
Dunn, D. A., & Pinkert, C. A. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2288-8_18 · Cited by 3
Advanced therapies for inherited optic neuropathies
Wong, D., Makam, R., & Yu‐Wai‐Man, P. (2025) · Eye · doi:10.1038/s41433-025-04109-1 · Cited by 6
“In a trial from China, the rAAV2-ND4 vector was found to be safe in nine subjects [53, 54], and better visual outcomes were associated with age, earlier treatment and baseline BCVA [55, 56].”
Gene and cell-based therapies for retinal and optic nerve disease
Esposito, E. P., Han, I. C., & Johnson, T. V. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00016-2 · Cited by 5
Mitochondrial DNA: Structure, Genetics, Replication and Defects
Taanman, J., & Kroon, A. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811752-1.00005-5 · Cited by 6
Aung, M. H., Volpe, N. J., Choi, D., Stein, J. M., Goldstein, A., & Liu, G. T. (2022) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001651 · Cited by 3
Clinical Updates and Recent Developments in Neuro-Ophthalmology
Vuppala, A.-A. D., & Miller, N. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-25389-9_8 · Cited by 3
Ruberto, G., Guagliano, R., Barillà, D., Bensi, M., Fazzi, E. M., Galli, J., Rossi, A., Mazza, C., Manzoni, F., Domenegati, E., et al. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01432-2 · Cited by 3
Chou, T.-H., Hao, Z., Alba, D. E., Lazo, A., Afflitto, G. G., Eastwood, J. D., Porciatti, V., Guy, J. R., & Yu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317068 · Cited by 3
Dimopoulos, I. S., & Xu, M. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.04.062 · Cited by 3
Gombeau, K., Hoffmann, S. A., & Cai, Y. (2025) · Genetics · doi:10.1093/genetics/iyaf037 · Cited by 1
“2015; Wan et al .”
Technological advances in the diagnosis and management of inherited optic neuropathies
Britton, J. O. T., Yu‐Wai‐Man, P., & Chen, B. S. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1609033 · Cited by 4
“Both approaches use forms of an AAV2 vector to deliver a WT copy of the MT-ND4 gene, again via allotopic expression following intravitreal injection (41, 42). scAAV2-P1 ND4 v2 has demonstrated expression of MT-ND4 in non-human primates and a favourable safety profile in a mouse LHON model (43).”
Wu, X., Jin, H., Zhang, B., Yue, M., He, J., Shan, J., Hong, C., & Shen, T. (2026) · European journal of medical research · doi:10.1186/s40001-026-04091-8 · Cited by 3
Therapies Approaches in Mitochondrial Diseases
Emmanuele, V., Quinzii, C. M., & Hirano, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-70147-5_11 · Cited by 3
Les maladies mitochondriales de l’adulte : mise au point
Allouche, S., Schaeffer, S., & Chapon, F. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.12.002 · Cited by 4
The Challenges and Therapeutic Prospects in Eye Disease
Tsai, C.-C. (2023) · MDPI eBooks · doi:10.3390/books978-3-0365-8402-7 · Cited by 1
Dong, Y., Hao, Z., Liu, Y., Chang, A., Porciatti, V., Lam, B. L., Jin, X., & Yu, H. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.14.58 · Cited by 1
Administration of Ocular Gene Therapy
Xu, D. N., Khan, M., Klufas, M. A., & Ho, A. C. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000365 · Cited by 1
Adeno-associated Viral Vectors in the Retina: Delivering Gene Therapy to the Right Destination
Rudnick, N. D., Kim, L. A., & Comander, J. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000416 · Cited by 1
Hassan, A. K., Mohsen, M., & Serhan, H. A. A. (2024) · Neuro-Ophthalmology · doi:10.1080/01658107.2024.2360413 · Cited by 1
“21 This meta-analysis aims to compare the visual outcomes between treated and nontreated eyes with rAAV2-ND4 intravitreal injection in the treatment of LHON.”
Sergott, R. C., Carelli, V., Newman, N. J., Biousse, V., Yu‐Wai‐Man, P., Vignal‐Clermont, C., Josse, C., Taiel, M., Sahel, J., Barboni, P., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.9.42 · Cited by 2
“…with other similar AAV-based therapy products developed by two independent research groups (Guy et al. group, Bascom Palmer Eye Institute, Miami, FL, USA; Li et al. group, Wuhan, China), 27–30 acknowledging a consistent and reproducible effect of AAV-based intravitreal gene therapy in MT-ND4 LHON.”
Un cas de neuropathie optique héréditaire de Leber chez un mélanoderme africain
Ayena, K. D., Tchedre, K. T., Vonor, K., Santos, K. M. A., Nagbé, Y., Mouad, L., & Balo, K. P. (2017) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2016.10.021 · Cited by 1
Visual Acuity Testing Before and After Intravitreal Injection of rAAV2-ND4 in Patients
Li, B., & Wu, C. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_22 · Cited by 1
Self-citationTreatment of Leber Hereditary Optic Neuropathy
Yu‐Wai‐Man, P., & Lam, B. L. (2019) · Springer eBooks · doi:10.1007/978-3-319-98455-1_14 · Cited by 1
Improving the visual outcome in Leber's hereditary optic neuropathy: Framework for the future
Asanad, S., Frousiakis, S. E., Wang, M. Y., Fantini, M., Sultan, W., Wood, T. D., Nwako, F. U., Karanjia, R., & Sadun, A. A. (2019) · Journal of Current Ophthalmology · doi:10.1016/j.joco.2019.05.004 · Cited by 1
Suprachoroidal Delivery of Subretinal Gene and Cell Therapy
Xu, D. N., Ma, K., & Ho, A. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-76853-9_9 · Cited by 1
Chen, J. J.-W., & Brodsky, M. C. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.02.030 · Cited by 1
Trial Interventions in ABCA4- RetinopathyPreprint
Breiki, M. A. (2020) · doi:10.14293/s2199-1006.1.sor-.ppz0nmp.v1 · Cited by 1
“To date, there have been successful outcomes of the application of rAAV to Neurodegenerative Diseases in individuals with Parkinson's disease and Leber's inherited Optic Neuropathy (LHON) as demonstrated by safety and efficacy studies [5, 33].”
BackgroundOcular Gene Therapy—The Future Is Now
Huang, S. S., High, K. A., & Toso, R. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000216
Newman, N. J. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000471
Curado, T. F. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-13062017-162234
Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Leber Hereditary Optic Neuropathy
Xie, K., Ming, S., Yang, M., Jin, X., & Lei, B. (2018) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-13-0884-0_22
Treatment options for Leber hereditary optic neuropathy
Povilaityte, I., & Liutkevičienė, R. (2018) · Neurologijos seminarai · doi:10.29014/ns.2018.32
Punzo, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00019-8 · Cited by 1
Development of plasmid DNA nanoparticles for mitochondrial gene therapy
Costa, D. R. B., de Sousa, F. P., & Queiroz, J. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818435-6.00011-6
Future perspectives of biological macromolecules in biomedicine
Neves, A. R., Faria, R., Albuquerque, T., Quintela, T., Sousa, Â., & Costa, D. R. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85759-8.00026-9
Nanotechnology to Correct Mitochondrial Disorders in Cancer Diseases
Faria, R., Albuquerque, T., Neves, A. R., Sousa, Â., & Costa, D. R. B. (2022) · Springer eBooks · doi:10.1007/978-3-031-17831-3_6
Toxic Medications in Mitochondrial Optic Neuropathies
Liu, H., & Sadun, A. A. (2023) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2023.03.003
Silva, V. D. O. E., Mendes, J. K. D. S., de Barros, V. A., Maximino, M. D. S., Medeiros, L., & da Silva, A. H. P. (2023) · Revista Brasileira de Oftalmologia · doi:10.37039/1982.8551.20230041
“(4,6,20,23,37) Sequelas anatômicas não foram documentadas por exame de fundo de olho, e nenhuma perda de visão foi relatada devido a tratamento ou efeitos adversos, mas pelo curso clínico da doença.”
Hassan, A. K., & Serhan, H. A. A. (2025) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2898_23
“Most of the studies were published in 2021, with five studies being published in 2021, [12–16] followed by 2020 with four studies, [17–20] two studies being published in 2016 [21,22] and 2022 [23,24] each, and one study each in 2011, [5] 2013, [6] 2019, [25] and 2023 [26] [Fig .”
InfluentialAnimal Models in Neuro Ophthalmology
Normando, E. M., Sher, A., Patel, R. P., Arora, N., & Cordeiro, M. F. (2025) · Springer eBooks · doi:10.1007/978-3-031-72156-4_19
Development of Two In Vitro ND1 -LHON Models for Evaluating Gene Therapy Efficacy
Li, X., Yuan, J. J., Chen, Z., Zhang, Y., Liu, Y., & Zhang, Y. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.13.34 · Cited by 1
Gene Therapy for Leber Hereditary Optic Neuropathy (LHON): A Systematic Review and Meta-Analysis
Alghamdi, L. N., Alsudais, A. S., Almarwani, S. H., Alraddadi, R. A., Alsamadani, A. H., Alnamlah, A. A., Aljehani, S., Allarakia, Y. F., Alghamdi, A. M., & Alshowaeir, D. (2026) · Neuro-Ophthalmology · doi:10.1080/01658107.2026.2624440
“8 The m.11778 G > A variant is the most prevalent worldwide and is associated with the poorest visual prognosis, whereas the m.14484T > C mutation carries a relatively higher chance of spontaneous recovery.”
Gene Therapy Against Hereditary Diseases
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_8
Mitochondrial insufficiencies and neuroprotection in glaucoma
Sundaram, R. P., Pattamatta, U., & White, A. J. R. (2026) · International Ophthalmology · doi:10.1007/s10792-026-04158-9
“An open-label gene therapy trial conducted in a small sample of LHON patients demonstrated that intravitreal injection of recombinant adeno-associated virus with ND4 improved visual field measures in six of nine patients without any change in nerve fibre layer and no adverse outcomes [64].”
Ambika, S., & Sundaramurthy, S. (2026) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1696_25
“[62,63] Factors associated with better outcomes are young age onset of disease, shorter interval between disease onset and treatment.”
Karaa, A., Sanchez, M. I. G. L., Stuart, C., Bolliger, L., Murray, K., O'Hanlon, M. E., Tseng, B., Yeske, P. E., & Murray, S. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261473291
“37 Similarly, TK2 deficiency trials using survival and ventilatory outcomes have shown evidence of meaningful disease modification and altered disease trajectory.”
Gene therapy clinical trials for inherited eye diseases: The pediatric perspective
Sandali, A., Nikolaidou, A., Gianni, T., Tsoukala, Z., Tsinopoulos, I., & Lamprogiannis, L. P. (2026) · European Journal of Ophthalmology · doi:10.1177/11206721261478166
Zhang, X., Wei, X., & Wei, W. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00488-6 · Cited by 2
Gombeau, K., Wan, R., James, J. S., Tribouillard-Tanvier, D., & Cai, Y. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag986
“Multiple routes are being explored, among which gene therapy replacement, involving the allotopic expression of a healthy copy of a mitochondrial gene, is a promising candidate [ 22–24 ].”
Ocular Gene Therapy in China: Technological Framework, Clinical Translation, and Future Perspectives
Zhang, D., He, Z., Lu, F., & Yang, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261495300
Metadata
- Authors
- Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., Wang, D.-W., & Li, B.
- Affiliations
- Tongji Hospital (CN)
- Ezhou Central Hospital (CN)
- Sun Yat-sen University (CN)
- Corresponding author
- Li, Bin
- Venue
- Scientific Reports
- Published
- 2016-02-19
- Volume
- 6
- Issue
- 1
- Pages
- 21587-21587
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4759604
- OpenAlex
- W2397855699
- Cited by
- 182
- References
- 31
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 9 · 2023: 16 · 2022: 21 · 2021: 19 · 2020: 19 · 2019: 21 · 2018: 21 · 2017: 17 · 2016: 13
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (30872823, 30801260, 2010021, 81271015)
- Tongji University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- Leber's hereditary optic neuropathy, NADH dehydrogenase subunit 4, mitochondrial DNA mutations, intravitreal injection, visual acuity, visual field, retinal nerve fiber layer, treatment safety, mitochondrial disease
- MeSH terms
- Dependovirus, Administration, Oral, Adolescent, Adult, Child, Electroretinography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mutation, NADH Dehydrogenase, Plasmids, Prednisolone, Genetic Therapy, Treatment Outcome, Point Mutation, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence, Young Adult, HEK293 Cells, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.